Enhanced growth inhibition effect of Resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels

Colloids and Surfaces B: Biointerfaces

Volumn 72, Issue 1, 2009, Pages 40-47

  Shao, Junfei ^a   Li, Xiaolin ^b   Lu, Xiaowei ^a   Jiang, Chen ^a   Hu, Yong ^c   Li, Qingping ^a   You, Yongping ^a   Fu, Zhen ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^c NANJING UNIVERSITY   (China)

Author keywords

Controlled release; Glioma; Nanoparticles; Resveratrol; ROS

Indexed keywords

ANTI-CANCER AGENTS; APOPTOSIS; BIODEGRADABLE NANOPARTICLE; CELL-CYCLE ARREST; CELLULAR RESPONSE; CLINICAL FEASIBILITY; CONTROLLED RELEASE; DELIVERY SYSTEMS; DRUG FORMATION; ENCAPSULATION EFFICIENCY; ENHANCED GROWTH; EQUIVALENT DOSE; GLIOMA; GLIOMA CELLS; INTENSIVE RESEARCH; LIPOPHILICITY; MALIGNANT GLIOMA; NANO SCALE; POTENTIAL MODEL; REACTIVE OXYGEN SPECIES; RESVERATROL; ROS; TRADITIONAL CHINESE MEDICINE;

CELL DEATH; CYTOTOXICITY; DRUG THERAPY; ENCAPSULATION; LEAD; MOTION PICTURE EXPERTS GROUP STANDARDS; OXYGEN;

NANOPARTICLES;

ALPHA TOCOPHEROL; COPOLYMER; METHOXY POLY(ETHYLENE GLYCOL); NANOPARTICLE; POLYCAPROLACTONE; REACTIVE OXYGEN METABOLITE; RESVERATROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DEATH; CHINESE MEDICINE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; ENCAPSULATION; GLIOMA CELL; GROWTH INHIBITION; LIPOPHILICITY; NANOANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIODEGRADATION, ENVIRONMENTAL; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; GLIOMA; INTRACELLULAR SPACE; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PARTICLE SIZE; RATS; REACTIVE OXYGEN SPECIES; STILBENES; VITAMIN E;

EID: 67349197868     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2009.03.010     Document Type: Article

References (16)

1. Stewart L.A. Lancet 359 (2001) 1011-1018
2. Gusman J., Malonne H., and Atassi G. Carcinogenesis 22 (2001) 1111-1117
3. Joe A.K., Liu H., Suzui M., Vural M.E., Xiao D., and Weinstein I.B. Clin. Cancer Res. 8 (2002) 893-903
4. Kuwajerwala N., Cifuentes E., Gautam S., Menon M., Barrack E.R., and Veer Reddy G.P. Cancer Res. 62 (2002) 2488-2492
5. Schneider Y., Vincent F., Duranton B., Badolo L., Gosse F., Bergmann C., Seiler N., and Raul F. Cancer Lett. 158 (2000) 85-91
6. Juan M.E., Wenzel U., Daniel H., and Planas J.M. J. Agric. Food Chem. 56 (2008) 4813-4818
7. Li X., Li R., Qian X., Ding Y., Tu Y., Guo R., Hu Y., Jiang X., Guo W., and Liu B. Eur. J. Pharm. Biopharm. 70 (2008) 726-734
8. Liu B., Yang M., Li X., Qian X., Shen Z., Ding Y., and Yu L. J. Pharm. Sci. 97 (2008) 3170-3181
9. Wenzel U., Nickel A., and Daniel H. Apoptosis 10 (2005) 359-368
10. Fang J., Sawa T., Akaike T., and Maeda H. Cancer Res. 62 (2002) 3138-3143
11. Davda J., and Labhasetwar V. Int. J. Pharm. 233 (2002) 51-59
12. van Vlerken L.E., Duan Z., Seiden M.V., and Amiji M.M. Cancer Res. 67 (2007) 4843-4850
13. Shenoy D., Little S., Langer R., and Amiji M. Mol. Pharm. 2 (2005) 357-366
14. Laurent A., Nicco C., Chéreau C., Goulvestre C., Alexandre J., Alves A., Lévy E., Goldwasser F., Panis Y., Soubrane O., Weill B., and Batteux F. Cancer Res. 65 (2005) 948-956
15. Galati G., Sabzevari O., Wilson J.X., and O'Brien P.J. Toxicology 177 (2002) 91-104
16. Sun W., Wang W., Kim J., Keng P., Yang S., Zhang H., Liu C., Okunieff P., and Zhang L. Adv. Exp. Med. Biol. 614 (2008) 179-186